CN111184666A - Antiviral urea cream compound preparation - Google Patents

Antiviral urea cream compound preparation Download PDF

Info

Publication number
CN111184666A
CN111184666A CN202010102412.1A CN202010102412A CN111184666A CN 111184666 A CN111184666 A CN 111184666A CN 202010102412 A CN202010102412 A CN 202010102412A CN 111184666 A CN111184666 A CN 111184666A
Authority
CN
China
Prior art keywords
urea
antiviral
skin
compound preparation
hand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010102412.1A
Other languages
Chinese (zh)
Inventor
董达科
王国华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantong University
Affiliated Hospital of Jiangsu University
Affiliated Hospital of Jiangnan University
Original Assignee
Nantong University
Affiliated Hospital of Jiangnan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantong University, Affiliated Hospital of Jiangnan University filed Critical Nantong University
Priority to CN202010102412.1A priority Critical patent/CN111184666A/en
Publication of CN111184666A publication Critical patent/CN111184666A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708Rheum (rhubarb)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a novel antiviral urea cream compound preparation, which is used for moisturizing hand skin of the general public, in particular to clinical medical staff working at the epidemic prevention and disease treatment line and preventing virus infection. The invention takes urea, interferon and rhubarb as main components, and adds other matrixes simultaneously, and the antiviral urea cream compound preparation with stable process, exact curative effect and good safety is prepared by experimental screening and preparation. The antiviral urea cream compound preparation is used as hand cream for external use on hand skin, can play double roles of skin care and virus prevention, and greatly reduces the possibility of infection and transmission of various viruses through the hand skin.

Description

Antiviral urea cream compound preparation
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an antiviral urea cream compound preparation.
Background
The skin is the largest external organ of the human body and has an important barrier protection effect. The hand is the most easily exposed part, the skin of the hand can contact various substances every day, because cleaning needs to be carried out for many times every day, particularly, strict hand hygiene operation is needed for medical staff working at the front line of clinic, but the skin of the hand is easy to dry, desquamate and even chap after long-term and many times of cleaning, the appearance is not only influenced, but also the barrier protection effect of the skin is seriously damaged, and the invasion of various pathogens is easily caused. Currently, China is in a special stage of resisting novel coronavirus pneumonia, a large number of front-line medical staff have obvious rough and dry skin after extremely strict hand hygiene operations every day due to protection requirements, and the external hand cream is urgently needed to improve and restore the barrier function of hand skin. In the 'novel pneumonia diagnosis and treatment scheme for coronavirus infection' published by the national Weijian Commission, respiratory droplets and contact transmission are clearly pointed out as main transmission paths for the transmission paths of viruses, so that except that a mask is worn to prevent the respiratory transmission, a novel skin moisturizer which has the effects of moisturizing the skin and preventing viruses is developed and matched with the cleaning and disinfection of the skin to carry out skin care, and the possibility of contact transmission can be better avoided. For a wide range of people, the hand cream with the double functions of skin care and virus prevention is applied for daily care, and the possibility of infecting and spreading various viruses through the skin of hands can be greatly reduced. However, through literature search, at present, no antiviral urea cream compound preparation type hand cream or skin lotion with double functions of skin care and virus prevention exists at home and abroad. Therefore, the novel antiviral urea cream compound preparation has very important clinical value, social value and economic value for clinical medical staff and epidemic prevention needs of the general public.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide an antiviral urea cream compound preparation which can be used for moistening hand skin and has an important function of effectively preventing virus infection for the broad public, particularly clinical medical staff working at the first line of epidemic prevention and treatment.
In order to achieve the purpose, the invention adopts the following technical scheme:
the antiviral urea cream compound preparation is prepared from an oil phase and a water phase, wherein the oil phase comprises: 110-120 g of stearic acid, 50-150 g of liquid paraffin, 0-15 g of lanolin and 0-20 g of vaseline; the aqueous phase comprises: 110-150 g of urea, 100-300 ten thousand IU of interferon, 100-200 mg of rhubarb extract, 15-20 g of triethanolamine, 30-60 g of glycerol and distilled water with constant volume of 1000 mL.
The preparation method of the composite preparation comprises the following steps: heating the oil phase component in water bath to melt and keep the temperature at 65-80 ℃, heating the water phase component in water bath to dissolve, keeping the temperature at 65-80 ℃, slowly adding the water phase into the oil phase, and continuously stirring in the same direction to obtain the semisolid substance.
The antiviral urea cream compound preparation is used as hand cream for the general public, in particular to hand skin moisturizing and virus infection prevention of clinical medical staff working at the first line of epidemic prevention and disease treatment. The main components of the antiviral urea cream compound preparation type hand cream prepared by the invention are urea, interferon and a Chinese medicinal rhubarb extract. Wherein the urea is capable of increasing the hydration of the stratum corneum of the skin and softening the skin. Interferon has broad-spectrum antiviral, antitumor and immunoregulatory effects, and its therapeutic effect is well-known by clinical scientists at home and abroad. The Chinese medicine rhubarb extract has powerful anti-infection, antisenility and antioxidant functions, and has the functions of regulating immunity, resisting inflammation, clearing away heat and toxic material, resisting pathogenic microbe, etc. the Chinese patent shows that rhubarb has the function of inhibiting influenza virus, SARS virus, herpes virus and other viruses. The invention takes urea, interferon and rhubarb as main components, and adds other matrixes simultaneously, and the antiviral urea cream compound preparation with stable process, exact curative effect and good safety is prepared by experimental screening and preparation. The anti-virus urea cream compound preparation type hand cream can play double roles of skin care and virus prevention when being externally applied to hand skin, and greatly reduces the possibility of infecting and spreading various viruses through the hand skin.
Compared with the traditional hand cream, the hand cream has the following beneficial effects:
1. the hand washing liquid has the double functions of skin care and virus prevention, reduces the influence on the damage of the barrier function of the hand skin after repeated hand washing, and greatly reduces the possibility of transmitting various viruses through hand contact.
2. Before wearing the protective tool, clinical first-line medical staff can be coated on the part of the skin, so that a layer of lipid film is formed on the surface of the skin, the skin is protected, the friction is reduced, the excessive hydration is prevented, sweat and possible virus invasion are isolated, and a better protective effect is achieved.
3. Can effectively enhance the protection requirements of medical staff and the common people, especially in the special period of the prior art for resisting the novel coronavirus pneumonia.
4. Can be used as health skin care product, or topical medicine.
5. The preparation process is simple, the price is low, and the method is suitable for large-scale popularization.
Detailed Description
The following examples further illustrate the present invention but are not to be construed as limiting the invention. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention. The experimental methods and reagents of the formulations not specified in the examples are in accordance with the conventional conditions in the art.
Example 1
The prescription composition is as follows: the oil phase of the product is: 110g of stearic acid, 70g of liquid paraffin and 20g of vaseline; the water phase comprises 110g of urea, 200 ten thousand IU of interferon, 150mg of rhubarb extract, 18g of triethanolamine, 60g of glycerol and distilled water with constant volume of 1000 ml. Making into oil-in-water cream.
Preparation: and (3) putting the oil phase component into a proper container to be heated in a water bath to melt and keep the temperature at about 65-80 ℃, putting the water phase component into another beaker to be heated in a water bath to dissolve, keeping the temperature at about 65-80 ℃, slowly adding the water phase into the oil phase, and continuously stirring in the same direction to obtain a semi-solid substance.
Example 2
The prescription composition is as follows: the oil phase of the product is: 115g of stearic acid, 150g of liquid paraffin and 15g of lanolin; the water phase comprises 140g of urea, 300 ten thousand IU of interferon, 100mg of rhubarb extract, 18g of triethanolamine, 40g of glycerol and distilled water with constant volume of 1000 ml. Making into oil-in-water cream.
Preparation: and (3) putting the oil phase component into a proper container to be heated in a water bath to melt and keep the temperature at about 65-80 ℃, putting the water phase component into another beaker to be heated in a water bath to dissolve, keeping the temperature at about 65-80 ℃, slowly adding the water phase into the oil phase, and continuously stirring in the same direction to obtain a semi-solid substance.
Example 3
The prescription composition is as follows: the oil phase of the product is: 115g of stearic acid, 120g of liquid paraffin and 15g of vaseline; the water phase comprises 140g of urea, 300 ten thousand IU of interferon, 120mg of rhubarb extract, 18g of triethanolamine, 45g of glycerol and distilled water with constant volume of 1000 ml. Making into oil-in-water cream.
Preparation: and (3) putting the oil phase component into a proper container to be heated in a water bath to melt and keep the temperature at about 65-80 ℃, putting the water phase component into another beaker to be heated in a water bath to dissolve, keeping the temperature at about 65-80 ℃, slowly adding the water phase into the oil phase, and continuously stirring in the same direction to obtain a semi-solid substance.
The prepared hand cream was evaluated for efficacy and safety as follows:
1. and (4) checking the quality of a finished product:
(1) general examination: appropriate amount of each of 3 batches of finished products was taken and checked for appearance, spreadability, greasiness, etc. The result shows that the finished product has fine appearance, smooth hand feeling, easy unfolding after external coating, no grain feeling and no layering phenomenon.
(2) And (4) checking the stability: taking 3 batches of finished products, uniformly filling the finished products into a closed container, respectively placing the finished products in a thermostat, at room temperature (25 +/-3) DEG C and in a refrigerator (5 +/-2) DEG C for one month, and checking results show that the finished products have no obvious changes in consistency, color, uniformity and the like and have no phenomena of mildew and the like.
(3) Moisture retention test: white paper is cut into a certain size, a layer of antiviral urea cream compound preparation sample is uniformly coated after precise weighing, the sample is weighed, and the sample is taken out and weighed after being placed at 25 +/-l ℃ for 4 hours without obvious change, so that the moisturizing performance of the antiviral urea cream compound preparation is proved to be better.
2. Determination of interferon biological activity: a micro cytopathic inhibition method (CPE) is adopted, WISH cells/VSV virus is used as a basic detection system, and the calibration is IU by using national reference products. The measured result shows that the potency of 3 batches of finished products meets the biological activity of 2.0 multiplied by 104IU/g or above.
3. Skin irritation test: adult rabbits were selected as 12 animals and randomly divided into 4 groups of 3 animals, 3 test groups and 1 vehicle group. The animals in the experimental group were administered 0.5g of the antiviral urea cream complex formulation applied to the skin of the backs of the dehaired rabbits (2.5 cm)2) After 24h, redness, blistering, congestion or other allergic phenomena were observed. Vehicle group animals were given only a base application of the antiviral urea cream complex formulation. The results showed that no local skin abnormality was observed in the test group through the skin irritation test.

Claims (4)

1. The antiviral urea cream compound preparation is characterized in that: is prepared from an oil phase and an aqueous phase, wherein the oil phase comprises: 110-120 g of stearic acid, 50-150 g of liquid paraffin, 0-15 g of lanolin and 0-20 g of vaseline; the aqueous phase comprises: 110-150 g of urea, 100-300 ten thousand IU of interferon, 100-200 mg of rhubarb extract, 15-20 g of triethanolamine, 30-60 g of glycerol and distilled water with constant volume of 1000 mL.
2. A method for producing the composite preparation according to claim 1, characterized in that: the method comprises the following steps: heating and melting the oil phase component under the water bath condition, keeping the temperature at 65-80 ℃, heating and dissolving the water phase component under the water bath condition, keeping the temperature at 65-80 ℃, slowly adding the water phase into the oil phase, and continuously stirring the mixture in the same direction to obtain the semisolid substance.
3. Use of the complex formulation of claim 1 in the preparation of a skin care product.
4. Use according to claim 3, characterized in that: the skin care product is hand cream, skin lotion, and facial skin lotion.
CN202010102412.1A 2020-02-19 2020-02-19 Antiviral urea cream compound preparation Pending CN111184666A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010102412.1A CN111184666A (en) 2020-02-19 2020-02-19 Antiviral urea cream compound preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010102412.1A CN111184666A (en) 2020-02-19 2020-02-19 Antiviral urea cream compound preparation

Publications (1)

Publication Number Publication Date
CN111184666A true CN111184666A (en) 2020-05-22

Family

ID=70687409

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010102412.1A Pending CN111184666A (en) 2020-02-19 2020-02-19 Antiviral urea cream compound preparation

Country Status (1)

Country Link
CN (1) CN111184666A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1449740A (en) * 2003-05-14 2003-10-22 长春长生基因药业股份有限公司 Virus-killing alpha interferon series medicinal cosmetics
CN102335416A (en) * 2011-09-30 2012-02-01 青岛绿曼生物工程有限公司 Compound Chinese medicinal composition for treating hog cholera and preparation method thereof
CN109330943A (en) * 2018-11-23 2019-02-15 茂名市和香种植科技有限公司 A kind of Chinese medicine agalloch eaglewood hand lotion and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1449740A (en) * 2003-05-14 2003-10-22 长春长生基因药业股份有限公司 Virus-killing alpha interferon series medicinal cosmetics
CN102335416A (en) * 2011-09-30 2012-02-01 青岛绿曼生物工程有限公司 Compound Chinese medicinal composition for treating hog cholera and preparation method thereof
CN109330943A (en) * 2018-11-23 2019-02-15 茂名市和香种植科技有限公司 A kind of Chinese medicine agalloch eaglewood hand lotion and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEOK-SANG HWANG ET AL: "Effects of Rhei Undulati Rhizoma on lipopolysaccharide-induced neuroinflammation in vitro and in vivo", 《ENVIRONMENTAL TOXICOLOGY》 *
张卫明 等主编: "《一带一路经济植物》", 30 November 2017, 东南大学出版社 *

Similar Documents

Publication Publication Date Title
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
CN109044915B (en) Infant hip-protecting cream and preparation process thereof
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
US4256763A (en) Treatment of herpes simplex infections and acne
KR20170036098A (en) Applications of phillyrin/phillygenin composition in preparing drugs or health care products for relieving and/or treating viral diseases
AU2004251720B2 (en) Method for treatment of sores and lesions of the skin
US20090220440A1 (en) Spray Composition for Topical Use for Treating and/or Preventing Herpes Simplex Labial Infections
CN1171588C (en) Method of treatment of seborrheic dermatitis
WO2010039654A2 (en) Topical treatment of skin infection
CN106389139A (en) Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof
CN110538313A (en) Broad-spectrum malassezia-resistant natural product composition and application
US7179495B1 (en) Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
CN103301065A (en) Nasal spray of seaweed extract and preparation method of nasal spray
JPH0987188A (en) Skin preparation for external use and bathing agent
JPH03178916A (en) Skin external agent
CN111184666A (en) Antiviral urea cream compound preparation
Cornbleet Discoid Lupus Erythematosus Treated with Plaguenil
US5075340A (en) Retinoic acid glucuronide preparations for application to the skin
CN111012717A (en) Antiviral vitamin E cream composite preparation
CA1218608A (en) Undecylenic acid as a treatment for herpes labialis
CN105534830B (en) A kind of maintenance method of bandage type body film and body skin
CN104306397A (en) Antibacterial external use ointment and manufacturing method thereof
CN108653304A (en) A kind of pterostilbene nano-micelle external-use gel and preparation method thereof
CN106362141A (en) Safe and multi-effect freckle removing agent and preparation method thereof
CN103751613B (en) A kind of Chinese medicinal liniment treating wind heat blood-dryness type seborrheic dermatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200522

RJ01 Rejection of invention patent application after publication